search
Back to results

CGM Plus GEM in Prediabetes (IMPEDE)

Primary Purpose

PreDiabetes

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
GEM
Routine Care
Sponsored by
University of Colorado, Denver
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for PreDiabetes focused on measuring prediabetes, lifestyle guide, continuous glucose monitor, prevention

Eligibility Criteria

25 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 25-70 years
  • A1C 6.0-6.4
  • Documented diagnosis of prediabetes
  • Have a smart phone
  • Able to read English, as the GEM guide is currently only available in English
  • Willing and able to follow the study procedures as instructed

Exclusion Criteria:

  • Diagnosis of diabetes mellitus
  • Currently taking any diabetes medication
  • Currently taking medication that promotes insulin resistance or otherwise interferes with metabolic control (e.g., prednisone)
  • Has a condition that precludes a low carbohydrate diet, such as gastroparesis
  • Has a physical or medical condition that precludes walking 120 steps per minute for 10 minutes or longer
  • Has documented kidney disease that would preclude participation in study per PI discretion
  • Active or planned cancer treatment
  • Extreme visual or hearing impairment that would impair ability to use real-time CGM
  • Pregnant or anticipates becoming pregnant in the next 4 months
  • Anticipates moving within the next 4 months
  • Treating physician, for any reason, considers their patient inappropriate for the study (e.g., uncontrolled bipolar disease)

Sites / Locations

  • University of Colorado- Anschutz Medical CampusRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

GEM + CGM + Activity Monitor

Routine Care

Arm Description

GEM plus CGM and Activity Monitor (FitBit)

Usual care already being received for prediabetes as treated by their care team.

Outcomes

Primary Outcome Measures

Change in percentage of CGM glucose readings > 120 mg/dL
Change in percentage of CGM glucose readings > 120 mg/dL from pre-intervention blinded CGM to post-intervention blinded CGM.

Secondary Outcome Measures

Change in HbA1c
Change in HbA1c from baseline to post-intervention.
Change in Glucose Variability
Change in glucose variability (GV%) as measured by CGM, from baseline to post-intervention.
Change in Body Mass Index
Change in Body Mass Index (BMI) from baseline to post-intervention.
Change in Cardiovascular Risk
Change in cardiovascular risk as calculated by a validated risk calculator from baseline to post-intervention
Change in Empowerment
Change in empowerment as measured by modified Diabetes Empowerment Scale, from baseline to post-intervention.
Change in Depressive Symptoms
Change in depression score as measured by PHQ-8 at baseline and post-intervention.
Change in Diabetes Knowledge
Change in diabetes knowledge as measured by a modified Diabetes Knowledge Scale from baseline to post-intervention.
Dietary Habits
Change in dietary habits as measured by Carbohydrate Routine Consumption Scale from baseline to post-intervention.
Motivation and Attitudes Toward Changing Health
Change in Motivation and Attitudes Toward Changing Health (MATCH) score from baseline to post-intervention.

Full Information

First Posted
October 6, 2022
Last Updated
November 2, 2022
Sponsor
University of Colorado, Denver
Collaborators
Abbott Diabetes Care, University of Virginia
search

1. Study Identification

Unique Protocol Identification Number
NCT05580978
Brief Title
CGM Plus GEM in Prediabetes
Acronym
IMPEDE
Official Title
Libre 2 CGM Plus Glycemic Excursion mIniMization (GEM) in the Treatment of PrEDiabEtes
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2022 (Actual)
Primary Completion Date
July 2023 (Anticipated)
Study Completion Date
January 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver
Collaborators
Abbott Diabetes Care, University of Virginia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to look into the effect of a lifestyle management guide called GEM (Glycemic Excursion Minimization) alongside continuous glucose monitoring (CGM) and an activity monitor (FitBit) and the effect this can have on persons with prediabetes.
Detailed Description
For people with prediabetes, it may be possible to delay or prevent the progression to diabetes by reducing postprandial glucose (PPG). The Glycemic Excursion Minimization (GEM) lifestyle intervention guide can reduce PPG in people with type 2 diabetes and has been studied in this population with continuous glucose monitor (CGM) feedback to help the user learn what elevates and lowers their PPG. This study examines if the GEM lifestyle intervention guide plus continuous feedback from the FreeStyle Libre 2 CGM and FitBit will allow participants with prediabetes with HbA1c 6.0-6.4% to (1) improve their metabolic status by illustrating the effects of their routine food and physical activity choices on their glucose levels and variability, more than Routine Care (RC), and (2) to enhance these investigations by adding comprehensive plasma proteomics to the analyses. The investigators will recruit up to 36 adult participants with prediabetes through the University of Colorado, with the goal of having at least 30 participants complete the study. Participants will be randomized to the intervention or RC. Those randomized to the intervention will be given a GEM treatment manual, Libre2 CGM, and an activity monitor and will follow the GEM lifestyle intervention guide for 4 months. Those participants randomized to RC will follow recommendations from their primary care provider. RC participants will have the opportunity to receive GEM four months after consenting and completing the RC pre-post assessments if they meet eligibility criteria. It is anticipated that 50% of the RC participants will want/be able to cross over to GEM upon completion of RC. Pre-post blinded CGM data and activity data, clinical, and psychosocial outcomes will be collected and analyzed. It is anticipated that this pilot project will demonstrate the benefits of using GEM plus FreeStyle Libre 2 and FitBit to reduce percentage of CGM readings >120 mg/dL, from blinded pre-post FreeStyle Libre Pro, as well as reduce BMI and depressive symptoms and increase modified diabetes empowerment. Comprehensive proteomics will be measured on small samples of EDTA treated venous blood. Individual proteins and protein pathways will be measured for each of the participants.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PreDiabetes
Keywords
prediabetes, lifestyle guide, continuous glucose monitor, prevention

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
36 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
GEM + CGM + Activity Monitor
Arm Type
Experimental
Arm Description
GEM plus CGM and Activity Monitor (FitBit)
Arm Title
Routine Care
Arm Type
Active Comparator
Arm Description
Usual care already being received for prediabetes as treated by their care team.
Intervention Type
Behavioral
Intervention Name(s)
GEM
Intervention Description
The intervention group will be given Libre 2 supplies for 4 months, an activity monitor, and the 4-chapter GEM paper guide. The intervention group will complete a virtual or inperson study visit where they will receive instructions on how to apply their unblinded Freestyle Libre and connect it to the study account, as well as how to register their Fitbit to the study account. Participants will receive one telephone call to review use of the GEM Guide and call at two weeks and six weeks later when the probability of dropouts from lifestyle intervention peaks. Participants will follow the self-directed GEM guide for 4 months (a 1-month treatment period followed by a 3-month maintenance period) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM.
Intervention Type
Other
Intervention Name(s)
Routine Care
Intervention Description
Participant's current prediabetes treatment.
Primary Outcome Measure Information:
Title
Change in percentage of CGM glucose readings > 120 mg/dL
Description
Change in percentage of CGM glucose readings > 120 mg/dL from pre-intervention blinded CGM to post-intervention blinded CGM.
Time Frame
4.5 months
Secondary Outcome Measure Information:
Title
Change in HbA1c
Description
Change in HbA1c from baseline to post-intervention.
Time Frame
4.5 months
Title
Change in Glucose Variability
Description
Change in glucose variability (GV%) as measured by CGM, from baseline to post-intervention.
Time Frame
4.5 months
Title
Change in Body Mass Index
Description
Change in Body Mass Index (BMI) from baseline to post-intervention.
Time Frame
4.5 months
Title
Change in Cardiovascular Risk
Description
Change in cardiovascular risk as calculated by a validated risk calculator from baseline to post-intervention
Time Frame
4.5 months
Title
Change in Empowerment
Description
Change in empowerment as measured by modified Diabetes Empowerment Scale, from baseline to post-intervention.
Time Frame
4.5 months
Title
Change in Depressive Symptoms
Description
Change in depression score as measured by PHQ-8 at baseline and post-intervention.
Time Frame
4.5 months
Title
Change in Diabetes Knowledge
Description
Change in diabetes knowledge as measured by a modified Diabetes Knowledge Scale from baseline to post-intervention.
Time Frame
4.5 months
Title
Dietary Habits
Description
Change in dietary habits as measured by Carbohydrate Routine Consumption Scale from baseline to post-intervention.
Time Frame
4.5 months
Title
Motivation and Attitudes Toward Changing Health
Description
Change in Motivation and Attitudes Toward Changing Health (MATCH) score from baseline to post-intervention.
Time Frame
4.5 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 25-70 years A1C 6.0-6.4 Documented diagnosis of prediabetes Have a smart phone Able to read English, as the GEM guide is currently only available in English Willing and able to follow the study procedures as instructed Exclusion Criteria: Diagnosis of diabetes mellitus Currently taking any diabetes medication Currently taking medication that promotes insulin resistance or otherwise interferes with metabolic control (e.g., prednisone) Has a condition that precludes a low carbohydrate diet, such as gastroparesis Has a physical or medical condition that precludes walking 120 steps per minute for 10 minutes or longer Has documented kidney disease that would preclude participation in study per PI discretion Active or planned cancer treatment Extreme visual or hearing impairment that would impair ability to use real-time CGM Pregnant or anticipates becoming pregnant in the next 4 months Anticipates moving within the next 4 months Treating physician, for any reason, considers their patient inappropriate for the study (e.g., uncontrolled bipolar disease)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Britney K Prince, BS
Phone
303-724-8968
Email
Britney.prince@cuanschutz.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Elizabeth Westfeldt, BSN, RN
Phone
303-724-2445
Email
elizabeth.westfeldt@cuanschutz.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tamara Oser, MD
Organizational Affiliation
Associate Professor, Dept. Family Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado- Anschutz Medical Campus
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Britney Prince, BS
Phone
303-724-8968
Email
britney.prince@cuanschutz.edu
First Name & Middle Initial & Last Name & Degree
Tamara K Oser, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

CGM Plus GEM in Prediabetes

We'll reach out to this number within 24 hrs